Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methenamine Hippurate→

Methenamine Hippurate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
5714-73-8
Molecular formula
C15H21N5O3
Molecular weight
319.36 g/mol
Drug class
Urinary antisepticmethenamine salt of hippuric acid
Mechanism of action
In acidic urine, methenamine is hydrolysed to formaldehyde, which exerts nonspecific antibacterial activity within the urinary tract. Hippuric acid contributes urinary acidification; effectiveness depends on maintaining sufficiently acidic urine.
Indications / reported uses
  • Prophylaxis or suppressive treatment of recurrent urinary-tract infections after the active infection has been eradicated by appropriate antibacterial therapy; not for treatment of acute pyelonephritis or systemic infection

Sources: US DailyMed — Methenamine hippurate tablets, label updated 21 May 2026 · NLM MeSH — Methenamine hippurate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methenamine Hippurate Environmental Risk Assessment (ERA) (the Methenamine Hippurate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.